Determinants of the Establishment of Human Immunodeficiency Virus Type 1 Latency

Journal of Virology

Volumn 83, Issue 7, 2009, Pages 3078-3093

  Duverger, Alexandra ^a   Jones, Jennifer ^a   May, Jori ^a   Bibollet Ruche, Frederic ^b   Wagner, Frederic A ^a   Cron, Randall Q ^b   Kutsch, Olaf ^a,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTONE CODE; HOST CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LEUKEMIA CELL LINE; LONG TERMINAL REPEAT; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; VIRUS DNA CELL DNA INTERACTION; VIRUS GENE; VIRUS LATENCY; CELL LINE; METABOLISM; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CELL LINE; HIV-1; HUMANS; NF-KAPPA B; TRANSCRIPTION, GENETIC; VIRUS INTEGRATION; VIRUS LATENCY;

EID: 63149124261     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02058-08     Document Type: Article

References (62)

1. Adams, M., L. Sharmeen, J. Kimpton, J. M. Romeo, J. V. Garcia, B. M. Peterlin, M. Groudine, and M. Emerman. 1994. Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc. Natl. Acad. Sci. USA 91:3862-3866.
2. Agosto, L. M., J. J. Yu, J. Dai, R. Kaletsky, D. Monie, and U. O'Doherty. 2007. HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology 368: 60-72.
3. Bednarik, D. P., J. A. Cook, and P. M. Pitha. 1990. Inactivation of the HIV LTR by DNA CpG methylation: evidence for a role in latency. EMBO J. 9:1157-1164.
4. Bednarik, D. P., J. D. Mosca, and N. B. K. Raj. 1987. Methylation as a modulator of expression of human immunodeficiency virus. J. Virol. 61: 1253-1257.
5. Biswas, D. K., C. M. Ahlers, B. J. Dezube, and A. B. Pardee. 1993. Cooper ative inhibition of NF-kappa B and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat. Proc. Natl. Acad. Sci. USA 90:11044-11048.
6. Brooks, D. G., S. G. Kitchen, C. M. Kitchen, D. D. Scripture-Adams, and J. A. Zack. 2001. Generation of HIV latency during thymopoiesis. Nat. Med. 7:459-464.
7. Bushman, F. D., and R. Craigie. 1992. Integration of human immunodefi ciency virus DNA: adduct interference analysis of required DNA sites. Proc. Natl. Acad. Sci. USA 89:3458-3462.
8. Butera, S. T. 2000. Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities. Antivir. Res. 48:143-176.
9. Carbone, A., G. Gaidano, A. Gloghini, L. M. Larocca, D. Capello, V. Canzonieri, A. Antinori, U. Tirelli, B. Falini, and R. Dalla-Favera. 1998. Differ ential expression of BCL-6, CD138/syndecan-l, and Epstein-Barr virus-en coded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 91:747-755.
10. Carbone, A., A. Gloghini, L. M. Larocca, D. Capello, F. Pierconti, V. Can-zonieri, U. Tirelli, R. Dalla-Favera, and G. Gaidano. 2001. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-l defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 97: 744-751.
11. Cavert, W., D. W. Notermans, K. Staskus, S. W. Wietgrefe, M. Zupancic, K. Gebhard, K. Henry, Z. Q. Zhang, R. Mills, H. McDade, C. M. Schuwirth, J. Goudsmit, S. A. Danner, and A. T. Haase. 1997. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276: 960-964.
12. Chen, B. K., M. B. Feinberg, and D. Baltimore. 1997. The κB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth. J. Virol. 71:5495-5504.
13. Chun, T. W., L. Carruth, D. Finzi, X. Shen, J. A. DiGiuseppe, H. Taylor, M. Hermankova, K. Chadwick, J. Margolick, T. C. Quinn, Y. H. Kuo, R. Brookmeyer, M. A. Zeiger, P. Barditch-Crovo, and R. F. Siliciano. 1997. Quanti fication of latent tissue reservoirs and total body viral load in HIV-1 infec tion. Nature 387:183-188.
14. Chun, T. W., R. T. Davey, Jr., M. Ostrowski, J. Shawn Justement, D. Engel, J. I. Mullins, and A. S. Fauci. 2000. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 6:757-761.
15. Chun, T. W., D. Engel, M. M. Berrey, T. Shea, L. Corey, and A. S. Fauci. 1998. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95:8869-8873.
16. Chun, T. W., D. Engel, S. B. Mizell, L. A. Ehler, and A. S. Fauci. 1998. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J. Exp. Med. 188:83-91.
17. Chun, T. W., D. Engel, S. B. Mizell, C. W. Hallahan, M. Fischette, S. Park, R. T. Davey, Jr., M. Dybul, J. A. Kovacs, J. A. Metcalf, J. M. Mican, M. M. Berrey, L. Corey, H. C. Lane, and A. S. Fauci. 1999. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5:651-655.
18. Chun, T. W., and A. S. Fauci. 1999. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl. Acad. Sci. USA 96:10958-10961.
19. Chun, T. W., D. Finzi, J. Margolick, K. Chadwick, D. Schwartz, and R. F. Siliciano. 1995. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1:1284-1290.
20. Chun, T. W., J. S. Justement, S. Moir, C. W. Hallahan, J. Maenza, J. I. Mullins, A. C. Collier, L. Corey, and A. S. Fauci. 2007. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J. Infect. Dis. 195:1762-1764.
21. Chun, T. W., L. Stuyver, S. B. Mizell, L. A. Ehler, J. A. Mican, M. Baseler, A. L. Lloyd, M. A. Nowak, and A. S. Fauci. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94:13193-13197.
22. Corbeil, J., D. Sheeter, D. Genini, S. Rought, L. Leoni, P. Du, M. Ferguson, D. R. Masys, J. B. Welsh, J. L. Fink, R. Sasik, D. Huang, J. Drenkow, D. D. Richman, and T. Gingeras. 2001. Temporal gene regulation during HIV-1 infection of human CD4+ T cells. Genome Res. 11:1198-1204.
23. Coull, J. J., F. Romerio, J. M. Sun, J. L. Volker, K. M. Galvin, J. R. Davie, Y. Shi, U. Hansen, and D. M. Margolis. 2000. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J. Virol. 74:6790-6799.
24. Doerre, S., P. Sista, S. C. Sun, D. W. Ballard, and W. C. Greene. 1993. The c-rel protooncogene product represses NF-kappa B p65-mediated transcrip tional activation of the long terminal repeat of type 1 human immunodefi ciency virus. Proc. Natl. Acad. Sci. USA 90:1023-1027.
25. Duh, E. J., W. J. Maury, T. M. Folks, A. S. Fauci, and A. B. Rabson. 1989. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kB sites in the long terminal repeat. Proc. Natl. Acad. Sci. USA 86:5974-5978.
26. Dunne, A. L., H. Siregar, J. Mills, and S. M. Crowe. 1994. HIV replication in chronically infected macrophages is not inhibited by the Tat inhibitors Ro-5-3335 and Ro-24-7429. J. Leukoc. Biol. 56:369-373.
27. Finzi, D., J. Blankson, J. D. Siliciano, J. B. Margolick, K. Chadwick, T. Pierson, K. Smith, J. Lisziewicz, F. Lori, C. Flexner, T. C. Quinn, R. E. Chaisson, E. Rosenberg, B. Walker, S. Gange, J. Gallant, and R. F. Siliciano. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517.
28. Folks, T. M, K. A. Clouse, J. Justement, A. Rabson, E. Duh, J. H. Kehrl, and A. S. Fauci. 1989. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc. Natl. Acad. Sci. USA 86:2365-2368.
29. Folks, T. M, J. Justement, A. Kinter, S. Schnittman, J. Orenstein, G. Poli, and A S. Fauci. 1988. Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J. Im munol. 140:1117-1122.
30. + T cells from human immunodeficiency virus type 1 (HlV-l)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J. Virol. 78:6122-6133.
31. Han, Y., Y. B. Lin, W. An, J. Xu, H. C. Yang, K. O'Connell, D. Dordai, J. D. Boeke, J. D. Siliciano, and R. F. Siliciano. 2008. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 4:134-146.
32. Hansen, S., and R. G. Leslie. 2006. TGN1412: scrutinizing preclinical trials of antibody-based medicines. Nature 441:282.
33. Haubrich, R. H., C. Flexner, M. M. Lederman, M. Hirsch, C. P. Pettinelli, R. Ginsberg, P. Lietman, F. M. Hamzeh, S. A. Spector, D. D. Richman, et al. 1995. A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. J. Infect. Dis. 172:1246-1252.
34. Ishida, T., A. Hamano, T. Koiwa, and T. Watanabe. 2006. 5′ long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals. Retrovirology 3:69.
35. Jones, J., J. Rodgers, M. Heil, J. May, L. White, J. A. Maddry, T. M. Fletcher III, G. M. Shaw, J. L. Hartman IV, and O. Kutsch. 2007. High throughput drug screening for human immunodeficiency virus type 1 reactivating com pounds. Assay Drag Dev. Technol. 5:181-189.
36. Jones, J., W. Whitford, F. Wagner, and O. Kutsch. 2007. Optimization of HIV-1 infectivity assays. BioTechniques 43:589-594.
37. Jordan, A, D. Bisgrove, and E. Verdin. 2003. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22:1868-1877.
38. Jordan, A., P. Defechereux, and E. Verdin. 2001. The site of HIV-1 integra tion in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J. 20:1726-1738.
39. Kao, S. Y., A F. Caiman, P. A. Luciw, and B. M. Peterlin. 1987. Antitermination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 330:489-493.
40. Kulkosky, J., G. Nunnari, M. Otero, S. Calarota, G. Dornadula, H. Zhang, A. Malin, J. Sullivan, Y. Xu, J. DeSimone, T. Babinchak, J. Stern, W. Cavert, A. Haase, and R. J. Pomerantz. 2002. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J. Infect. Dis. 186:1403-1411.
41. Kutsch, O., E. N. Benveniste, G. M. Shaw, and D. N. Levy. 2002. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J. Virol. 76:8776-8786.
42. Lehrman, G., I. B. Hogue, S. Palmer, C. Jennings, C. A. Spina, A. Wiegand, A. L. Landay, R. W. Coombs, D. D. Richman, J. W. Mellors, J. M. Coffin, R. J. Bosch, and D. M. Margolis. 2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366:549-555.
43. Lenasi, T., X. Contreras, and B. M. Peterlin. 2008. Transcriptional interfer ence antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 4:123-133.
44. Levy, D. N., G. M. Aldrovandi, O. Kutsch, and G. M. Shaw. 2004. Dynamics of HIV-1 recombination in its natural target cells. Proc. Natl. Acad. Sci. USA 101:4204-4209.
45. Mikovits, J. A., H. A. Young, P. Vertino, J. P. Issa, P. M. Pitha, S. Turcoski-Corrales, D. D. Taub, C. L. Petrow, S. B. Baylin, and F. W. Ruscetti. 1998. Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-γ) promoter and subsequent downregulation of IFN-γ production. Mol. Cell. Biol. 18:5166-5177.
46. Nabel, G., and D. Baltimore. 1987. An inducible transcription factor acti vates expression of human immunodeficiency virus in T cells. Nature 326: 711-713.
47. Pierson, T. C, Y. Zhou, T. L. Kieffer, C. T. Ruff, C. Buck, and R. F. Siliciano. 2002. Molecular characterization of preintegration latency in human immu nodeficiency virus type 1 infection. J. Virol. 76:8518-8531.
48. Pion, M., A. Jordan, A. Biancotto, F. Dequiedt, F. Gondois-Rey, S. Rondeau, R. Vigne, J. Hejnar, E. Verdin, and I. Hirsch. 2003. Transcriptional suppres sion of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J. Virol. 77:4025-4032.
49. Quivy, V., E. Adam, Y. Collette, D. Demonte, A. Chariot, C. Vanhulle, B. Berkhout, R. Castellano, Y. de Launoit, A. Burny, J. Piette, V. Bours, and C. Van Lint. 2002. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-κB and inhibitors of deacetylases: potential per spectives for the development of therapeutic strategies. J. Virol. 76:11091-11103.
50. Schneider, C. K., U. Kalinke, and J. Lower. 2006. TGN1412-a regulator's perspective. Nat. Biotechnol. 24:493-496.
51. Schroder, A. R., P. Shinn, H. Chen, C. Berry, J. R. Ecker, and F. Bushman. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521-529.
52. Sheridan, P. L., T. P. Mayall, E. Verdin, and K. A, Jones. 1997. Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev. 11:3327-3340.
53. Siliciano, J. D., J. Kajdas, D. Finzi, T. C. Quinn, K. Chadwick, J. B. Mar golick, C. Kovacs, S. J. Gange, and R. F. Siliciano. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9:727-728.
54. Siliciano, J. D., J. Lai, M. Callender, E. Pitt, H. Zhang, J. B. Margolick, J. E. Gallant, J. Cofrancesco, Jr., R. D. Moore, S. J. Gange, and R. F. Siliciano. 2007. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J. Infect. Dis. 195:833-836.
55. Siliciano, J. M., and R. F. Siliciano. 2005. Targeting HIV reservoirs with valproic acid. Hopkins HIV Rep. 17:8-9.
56. Smith, S. M. 2005. Valproic acid and HIV-1 latency: beyond the sound bite. Retrovirology 2:56.
57. Suntharalingam, G., M. R. Perry, S. Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, and N. Panoskaltsis. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355: 1018-1028.
58. + T cells in the absence of activating stimuli. J. Virol. 79:14179-14188.
59. Swindle, C. S., H. G. Kim, and C. A. Klug. 2004. Mutation of CpGs in the murine stem cell virus retroviral vector long terminal repeat represses si lencing in embryonic stem cells. J. Biol. Chem. 279:34-41.
60. Van Lint, C, S. Emiliani, M. Ott, and E. Verdin. 1996. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15:1112-1120.
61. Williams, S. A., L. F. Chen, H. Kwon, C. M. Ruiz-Jarabo, E. Verdin, and W. C. Greene. 2006. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25:139-149.
62. Winslow, B. J., R. J. Pomerantz, O. Bagasra, and D. Trono. 1993. HIV-1 latency due to the site of proviral integration. Virology 196:849-854.